ArticleJournal of the National Cancer Center2023
Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data.
Article in Journal of the National Cancer Center, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of tislelizumab in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2025Pooled it
- Tumor-associated lymphatic vessel density is a reliable biomarker for prognosis of esophageal cancer after radical resection: a systemic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Opening the black box: defining true-negative outcomes in esophageal cancer screening - a population-based study.BMC medicine · 2025Trial
- Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC.Frontiers in immunology · 2025Trial
- Glutamine transporter SLC1A5 inhibits autophagy-mediated CD276 degradation to promote esophageal cancer progression.Cancer biology & therapy · 2026Article
- Gambogenic acid globally regulates translational processes in Nrf2-mutant esophageal squamous cell carcinoma by promoting Nrf2/MafG protein multimerization.Acta pharmacologica Sinica · 2026Article
- Clinical characteristics and survival of esophageal cancer patients: annual report of the surgical treatment at Shanghai Chest Hospital, 2018.Journal of thoracic disease · 2026Article
- Development of a Combined Risk Factors Prediction Model for Esophageal Squamous Cell Carcinoma: A Secondary Analysis of the Linxian Nutrition Intervention Trial Cohort.Research square · 2026Article
- The oral microbiome is associated with the diagnosis, prognosis and radiotherapy sensitivity of esophageal cancer.Journal of translational medicine · 2026Article
- Effect of a nurse-led dyadic symptom management intervention on postoperative esophageal cancer patients and their family caregivers: A quasi-experimental trial with a qualitative process evaluation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Alcohol Consumption and Age-Specific Risk of Esophageal Cancer: Prospective Cohort Study.JMIR public health and surveillance · 2026Article
- To dye or not to dye? Comparing real-world diagnostic performance of white light, electronic, and Lugol's chromoendoscopy for esophageal squamous neoplasia.Surgical endoscopy · 2026Article
- Establishment of prognostic prediction model based on lipid metabolism related genes in esophageal squamous cell carcinoma by machine learning algorithms.BMC gastroenterology · 2026Article
- miR-3678-3p Promotes Esophageal Squamous Cell Carcinoma Progression by Regulating Phosphatase and Tensin Homolog.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Single-Cell RNA Sequencing Identifies a Distinct Epithelial Subpopulation Driving Resistance to Neoadjuvant Chemoimmunotherapy in Esophageal Squamous Cell Carcinoma.Biological procedures online · 2026Article
- Development and validation of a metabolic-inflammatory-nutritional prognostic model for esophageal squamous carcinoma.BMC cancer · 2026Article
- Is random biopsy necessary for normal esophageal mucosa during chromoendoscopy? Evidence from a population-based cohort study.BMC medicine · 2026Article
- Impact of hospital volume on outcomes of esophagectomy for esophageal cancer: analysis of a prospective multicenter database.Surgical endoscopy · 2026Article
- The consensus molecular subtypes of esophageal squamous cell carcinoma.Signal transduction and targeted therapy · 2026Article
- G protein-coupled receptor 137B drives malignant progression and May serves as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma.Cancer cell international · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal cancer poses a significant global burden, while its patterns and trends remain to be clarified. The aim of this study is to provide an update on the incidence and mortality rates of esophageal cancer and their trends in China based on data from the National Cancer Registry. Methods: We extracted data from the National Central Cancer Registry (NCCR) of China from 2000 to 2016 and performed comprehensive quality control. We calculated age-standardized rates of China (ASR China) and world (ASR world) using the Chinese population in 2000 and the Segi's world standard population, and performed a joinpoint regression analysis to examine the trend in incidence and mortality of esophageal cancer. The annual percent change (APC) and weighted average APC (AAPC) over the entire study period were estimated to measure the changing trend. Subgroup analyses were conducted by sex, region and pathological type. Results: A total of 487 eligible cancer registries were included in the data analysis and 22 registries with uninterrupted registration data were used for trend analysis. In 2016, there were an estimated of 184,500 incident cases of esophageal cancer and 142,300 deaths in China. The crude incidence, ASR China and ASR world were 25.25/100,000, 11.00/100,000 and 11.13/100,000, respectively. And the crude mortality, ASR China and ASR world were 19.38/100,000, 8.25/100,000 and 8.28/100,000, respectively. Esophageal squamous cell carcinoma (ESCC) was the most common histological type, accounting for 85.79% of all cases, followed by esophageal adenocarcinoma (EAC) (11.00%) and others (3.21%). There was a decreasing trend of ASR world in incidence and mortality during 2000-2016 with the AAPC of -4.6% (95% CI: -5.7%, -3.4%) and -4.6% (95% CI: -5.2%, -3.9%). The pattern and trend of esophageal cancer differ in sex, region and pathological type. Conclusions: The burden of esophageal cancer in China remains high with sex, regional and subtype differences. The incidence and mortality of esophageal cancer have continued to decline over the past decade, which was due in part to the reductions in risk factor exposure and the implementation of screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.